Clinical trials: Primary-progressive Multiple Sclerosis
Multiple Sclerosis, Pathologic Processes
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
The investigators are measuring the effectiveness of Ocrevus™ in helping patients with hand or arm weakness, especially if posed by a more advanced MS patient than those included in the clinical trials.
- Conditions
- Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases
- Trial name
- NCT03562975
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of South Florida
Multiple Sclerosis, Primary Progressive
Aerobic Exercises for Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) .It is the most common neurological disorders affecting young adults.Multiple sclerosis is an autoimmune disease that…
- Trial name
- NCT04545372
- Testing
- aerobic exercise
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- South Valley University
Primary Progressive Multiple Sclerosis
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)
The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.
- Trial name
- ORATORIO-Cort (NCT05974839)
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 732 people
- Sponsor
- State University of New York at Buffalo
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06138132
- Testing
- KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stanford University
Multiple Sclerosis, Relapse
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
Ocrelizumab is a humanized anti-CD20 monoclonal antibody that showed in phase III trials a powerful effect on relapse rate and lesion load accumulation in the relapsing form of multiple sclerosis (RMS).
- Conditions
- Multiple Sclerosis, Relapse, Primary Progressive Multiple Sclerosis
- Trial name
- INN-MS (NCT03691077)
- Testing
- Ocrelizumab
- Where
- France
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS)
Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis.
The goal of this clinical trial is to learn if an online wellness program can lower fatigue and improve mood and quality of life in people with progressive multiple sclerosis who are 45 to 70 years old and are experiencing…
- Trial name
- DEW (NCT07831928)
- Testing
- Online wellness course and online exercise platform, Usual Care Group
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- University of Iowa
Multiple Sclerosis
Wahls Paleo Diet and Progressive Multiple Sclerosis
Based on favorable preliminary data from ongoing studies testing the safety and tolerability of a nutrition, exercise and neuromuscular electrical stimulation funded by Direct MS, the investigators are proposing a pilot study…
- Trial name
- NCT01915433
- Testing
- Wahls Paleo Plus, Wahls Diet
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Terry L. Wahls
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- NCT07825389
- Testing
- C-CAR168
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- AbelZeta Inc.
Multiple Sclerosis
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
This is a multicentre non-interventional study aimed at evaluating the real-world effectiveness and safety of ocrelizumab treatment in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis…
- Trial name
- MuSicalE (NCT03593590)
- Testing
- Ocrelizumab
- Where
- 158 sites in Austria, Belgium and 23 more
- Volunteers
- 1,710 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
This study evaluates the effectiveness of N-acetyl cysteine (NAC) in the treatment of progressive multiple sclerosis. Half of the patients will receive NAC, while the other half will receive a placebo.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- NACPMS (NCT05122559)
- Testing
- N-acetyl cysteine
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Emmanuelle Waubant, MD PhD